ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MDNA Medicenna Therapeutics Corporation

0.157
0.00 (0.00%)
Pre Market
Last Updated: 20:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.1565
Ask Price 0.1612
News -
Day High

Low
0.151251

52 Week Range

High
0.5777

Day Low
Company Name Stock Ticker Symbol Market Type
Medicenna Therapeutics Corporation MDNA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.157 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.157
Trades Volume Avg Volume 52 Week Range
0 0 - 0.151251 - 0.5777
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.157 USD

Medicenna Therapeutics Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
135.79M 69.64M - 0 -10.05M -0.14 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Medicenna Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MDNA Message Board. Create One! See More Posts on MDNA Message Board See More Message Board Posts

Historical MDNA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.57770.57770.1512510.3401356241,203-0.4207-72.82%
3 Years3.72143.830.1512511.10164,922-3.56-95.78%
5 Years4.636.840.1512511.82161,652-4.47-96.61%

Medicenna Therapeutics Description

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.

Your Recent History

Delayed Upgrade Clock